Khalid Abousy
Cardiovascular Disease · Manassas, VANPI 1952358087
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 47 manufacturers, the largest accounting for just 24.0%. Reporting peaked in 2021 at $17,104 and has fallen 73.1% since, to $4,607 in 2025. Among cardiovascular disease clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 973 payments — averaging $70.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Esperion Therapeutics, Inc.$16K
- Novartis$13K
- Merck$9K
- Cvrx, Inc.$4K
- Cardiovascular Systems Inc.$3K
- Medtronic$2K
- plus $21K from 41 others
What the payments were for
- Consulting fees$5501%
- Speaking & faculty fees$31,06045%
- Travel & lodging$1,8213%
- Food & beverage$34,77151%
- Education$1070%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERQUVO$16,747
- NEXLETOL$15,509
- NEXLIZET$15,062
- ENTRESTO$10,046
- Barostim Neo System$2,875
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$1,304
- Diamondback Coronary$1,200
- XARELTO$696
- LEQVIO$590
- CAMZYOS$491
- FARXIGA$461
- GENERAL TACHY$399
- Repatha$397
- FFRct$363
- Resolute$351
- Ozempic$334
- ONYX FRONTIER$305
- SYMPLICITY G3$304
- ONYX 18$291
- KENGREAL$268
How this compares
$68,308 in reported general payments places this provider in the 95th percentile of 548 cardiovascular disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 260 | $394,046 |
| EntrestoSacubitril/Valsartan | 228 | $334,981 |
| XareltoRivaroxaban | 240 | $315,440 |
| EliquisApixaban | 164 | $189,110 |
| Repatha SureclickEvolocumab | 150 | $162,925 |
| JardianceEmpagliflozin | 93 | $128,837 |
| NexlizetBempedoic Acid/Ezetimibe | 118 | $105,972 |
| VerquvoVericiguat | 61 | $98,763 |
| FarxigaDapagliflozin Propanediol | 66 | $87,064 |
| CamzyosMavacamten | 11 | $74,801 |
| BrilintaTicagrelor | 78 | $65,721 |
| MounjaroTirzepatide | 28 | $39,549 |
| VascepaIcosapent Ethyl | 13 | $11,270 |
| Rosuvastatin Calcium | 630 | $9,902 |
| Ezetimibe | 378 | $9,404 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,505 | $394,046260 claims |
| NovartisEntresto | $13,101 | $334,981228 claims |
| Johnson & JohnsonXarelto | $1,754 | $315,440240 claims |
| PfizerEliquis | $728 | $189,110164 claims |
| AstraZenecaFarxiga, Brilinta | $1,579 | $152,786144 claims |
| Boehringer IngelheimJardiance | $879 | $128,83793 claims |
| Esperion Therapeutics, Inc.Nexlizet | $16,388 | $105,972118 claims |
| MerckVerquvo | $9,324 | $98,76361 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $1,246 | $74,80111 claims |
| Lilly USA, LLCMounjaro | $395 | $39,54928 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 548 cardiovascular disease providers in Virginia.
Other cardiovascular disease in Manassas
- Hamid TaheriManassas$501K
- Shahram YazdaniManassas$66K
- Balbir SidhuManassas$15K
- Shahryar MafiManassas$14K
- George VetrovecRichmond$2.3M
- Cyrus HadadiNorfolk$360K
- Michael AyersCharlottesville$305K
- David LimCharlottesville$264K
- Alexander TruesdellFalls Church$167K
- Antonio AbbateCharlottesville$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.